Neovacs, a French biotech company, is recruiting 30 patients for a placebo-controlled, proof-of-concept study to evaluate the production of anti-IFNα antibodies (an immune response) in adult subjects with dermatomyositis.
IFNα Kinoid is a therapeutic vaccine that targets the overproduction of cytokines (small proteins important in cell signaling) in autoimmune diseases. Overproduction of cytokines, such as interferon alpha, promotes inflammation and dysregulation of the immune system.
Recruitment is currently active at one site in Paris, with seven additional sites in Europe expected.
For more information, please contact Neovacs SA + 33 1 53 10 93 00.
Find more information about this trial here.
More information on other clinical trials for myositis can be found here.